1. Home
  2. Directory
  3. California
  4. Los Angeles
  5. Dermatology
  6. NPI Profile
  7. Prescriptions 1922130608

DR. NAISSAN OLIAI WESLEY M.D.
Prescription History 1922130608
Dermatology in Los Angeles, CA


Quality Rating: 77.86 out of 100 score

NPI Status: Active since March 09, 2007

Contact Information

9201 W SUNSET BLVD
SUITE 602
LOS ANGELES, CA
ZIP 90069
Phone: (310) 246-0495
Fax: (310) 246-0496

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. NAISSAN OLIAI WESLEY M.D., an active Dermatology specialist practicing in Los Angeles, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 61 documented patient claims. Among these therapy options, the most frequently utilized medication is Tretinoin, which accounts for 20 claims alone.

Medication Index

C
F
T
No matching medications currently found on file.

Ciclopirox

Generic Formulation: CiclopiroxSpecialty: Dermatology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
CA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills33.3
Peer Average Days Supply965
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $378.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.14

State Avg Cost Per Claim

$36.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane and pyridinone derivative that is used for the treatment of fungal infections of the skin and nails, and for treatment of VAGINAL YEAST INFECTIONS.

Therapeutic Applications

This medication is used to treat fungal infections of the fingernails and toenails. It is used as part of a treatment program that may include the removal of unattached, infected nails by a health care professional. Ciclopirox works by stopping the growth of fungus.

Clobetasol Propionate

Generic Formulation: Clobetasol PropionateSpecialty: Dermatology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 404
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills36.5
Peer Average Days Supply986
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.5% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $813.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.25

State Avg Cost Per Claim

$80.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.

Therapeutic Applications

This medication is used to treat a variety of skin conditions (such as eczema, psoriasis, dermatitis, allergies, rash). Clobetasol reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a very strong (super-high-potency) corticosteroid.

Fluorouracil

Generic Formulation: FluorouracilSpecialty: Dermatology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 380
CA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills46.3
Peer Average Days Supply1,219
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.5% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,046.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.49

State Avg Cost Per Claim

$90.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.

Therapeutic Applications

Fluorouracil is used to treat various types of cancer. It is a chemotherapy drug that is used to slow or stop cancer cell growth.

Tretinoin

Generic Formulation: TretinoinSpecialty: Dermatology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills19.7
Peer Average Days Supply555
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,248.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$112.42

State Avg Cost Per Claim

$118.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).

Therapeutic Applications

This medication is used to treat acne. It may decrease the number and severity of acne pimples and promote quick healing of pimples that do develop. Tretinoin belongs to a class of medications called retinoids. It works by affecting the growth of skin cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. NAISSAN OLIAI WESLEY M.D. provides transparency into local medical care patterns within Los Angeles, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Dermatology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.